[ACHN] Achillion Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 4.38 Change: 0.39 (9.77%)
Ext. hours: Change: 0 (0%)

chart ACHN

Refresh chart

Strongest Trends Summary For ACHN

ACHN is in the long-term down -79% below S&P in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on developing combination therapies for the treatment of chronic hepatitis C (HCV) infection and resistant bacterial infections. The company?s drug candidates for treating chronic HCV infection comprise Sovaprevir, a NS3/4A protease inhibitor, which has completed a Phase IIa clinical trial; ACH-3102, a NS5A inhibitor that is in Phase IIa clinical trial; ACH-3422, a NS5B nucleotide polymerase inhibitor, which has completed preclinical studies; and ACH-2684, a NS3/4A protease inhibitor that has completed Phase Ia and Ib clinical trials. It has a license and development agreement with Ora, Inc. for the development and commercialization of ACH-702, an antibacterial drug candidate that is delivered topically or locally. The company was founded in 1998 and is headquartered in New Haven, Connecticut.

Fundamental Ratios
Shares Outstanding EPS-0.47 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-9
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-25.83% ROE-27.14% ROI
Current Ratio19.64 Quick Ratio Long Term Debt/Equity Debt Ratio0.05
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities138.96 M Cash From Investing Activities-148.58 M Cash From Operating Activities-17.32 M Gross Profit
Net Profit-19.26 M Operating Profit-19.4 M Total Assets279.42 M Total Current Assets255.58 M
Total Current Liabilities13.01 M Total Debt610 K Total Liabilities13.41 M Total Revenue
Technical Data
High 52 week5.15 Low 52 week2.65 Last close3.1 Last change1.31%
RSI20.21 Average true range0.12 Beta0.8 Volume2.41 M
Simple moving average 20 days-9.36% Simple moving average 50 days-12.63% Simple moving average 200 days-13.92%
Performance Data
Performance Week-1.27% Performance Month-10.92% Performance Quart-26.37% Performance Half6.9%
Performance Year-26.01% Performance Year-to-date7.64% Volatility daily2.03% Volatility weekly4.55%
Volatility monthly9.32% Volatility yearly32.3% Relative Volume236.65% Average Volume1.22 M
New High New Low

News

2019-03-13 13:09:06 | Achillion Pharmaceuticals, Inc. NASDAQ:ACHN: Are Analysts Right About The Drop In Earnings?

2019-03-08 10:04:03 | Achillion ACHN Reports Narrower-Than-Expected Loss in Q4

2019-03-08 06:00:00 | Achillion to Present at the Barclays Global Healthcare Conference

2019-03-07 06:00:00 | Achillion Reports Fourth Quarter and Full Year 2018 Financial Results

2019-02-21 12:57:06 | Why a Connecticut pharma firm moved its C-suite to Blue Bell

2019-02-21 06:00:00 | Achillion Pharmaceuticals Expands Operations and Clinical Development into Philadelphia Area Office Market

2019-02-19 06:00:00 | Achillion to Present at the SVB Leerink 8th Annual Global Healthcare Conference

2019-02-12 07:50:00 | Research Report Identifies The Goodyear Tire & Rubber, Prudential Financial, PennyMac Mortgage Investment Trust, Achillion Pharmaceuticals, American Software, and Lantheus with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

2019-02-11 06:00:00 | Achillion Appoints Brian Di Donato as Chief Financial Officer

2019-02-04 12:45:05 | Alexion's ALXN Earnings Beat Estimates in Q4, Shares Up

2019-01-31 06:00:00 | Achillion Announces First Dosing in Phase 1 Multiple Ascending Dose Study of ACH-5228 Next-Generation Oral Factor D Inhibitor in Healthy Volunteers

2019-01-29 11:10:04 | Alexion's Ultomiris Meets Primary Endpoint in aHUS Study

2019-01-10 10:49:30 | Here's Why These Small-Cap Pharma Stocks Lost as Much as 45% in December

2019-01-10 05:00:00 | Top Picks 2019- Achillian Pharmaceuticals ACHN

2019-01-03 07:36:09 | The Daily Biotech Pulse: Aevi's ADHD Drug Flunks Mid-Stage Trial, Bristol-Myers To Buy Celgene, Teva Settles With Amgen

2019-01-03 06:00:00 | Achillion Announces Nicole Vitullo Elected to Chair the Board of Directors

2018-12-31 10:50:00 | 4 Healthcare Stocks That Are Raising Eyebrows

2018-12-20 16:30:00 | Why Achillion Pharmaceuticals Plunged for a 4th Consecutive Day

2018-12-19 15:45:00 | Why Achillion Pharmaceuticals Sank Again Today

2018-12-18 17:32:10 | Achillion Reports Positive Interim Data on Factor D Inhibitors

2018-12-18 16:33:00 | Why Rent-A-Center, Achillion Pharmaceuticals, and BP Prudhoe Bay Slumped Today

2018-12-18 15:02:00 | Why Achillion Pharmaceuticals Is Cratering Again Today

2018-12-18 08:00:31 | The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan

2018-12-18 06:50:00 | Today's Research Reports on Trending Tickers: Achillion Pharmaceuticals and Synergy Pharmaceuticals

2018-12-17 16:33:00 | Why Achillion Pharmaceuticals Crashed Today

2018-12-17 16:02:00 | Achillion Reports Positive Interim Data for ACH-4471 Phase 2 Trials and Provides Clinical Development Strategy Update

2018-12-16 14:18:20 | The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

2018-12-12 01:15:44 | Should You Buy Achillion Pharmaceuticals, Inc. ACHN?

2018-12-10 06:00:00 | Achillion Interim Clinical Trial Data and Strategic Update Planned for Dec 17th, 2018

2018-12-08 18:19:51 | RA Capital Was Wrong about Achillion Pharmaceuticals, Inc. ACHN: Is it Time To Buy?

2018-12-03 09:00:02 | Implied Volatility Surging for Achillion ACHN Stock Options

2018-11-07 06:30:01 | Achillion: 3Q Earnings Snapshot

2018-11-07 06:00:00 | Achillion Reports Third Quarter 2018 Financial Results

2018-10-18 13:14:42 | Does Achillion Pharmaceuticals Inc NASDAQ:ACHN Have A Volatile Share Price?

2018-10-17 07:40:00 | Investor Expectations to Drive Momentum within SunOpta, Acorda Therapeutics, Sapiens International Corporation N.V, The Descartes Systems Group, Achillion Pharmaceuticals, and CSS Industries — Discovering Underlying Factors of Influence

2018-09-25 06:00:00 | Achillion to Present at the Leerink Partners Roundtable Series

2018-09-14 09:09:01 | The Zacks Analyst Blog Highlights: Illumina, Celgene , Athersys and Achillion

2018-09-13 09:14:01 | IPOs and Foreign Investment Propel Biotech: 4 Top Picks

2018-09-10 06:00:00 | Achillion Appoints Paul Firuta Chief Operating Officer

2018-09-07 09:30:01 | Why Is Achillion ACHN Up 24.7% Since Last Earnings Report?

2018-08-31 04:14:08 | Achillion Pharmaceuticals ACHN Shares March Higher, Can It Continue?

2018-08-30 06:00:00 | Achillion to Present at the Baird 2018 Global Healthcare Conference

2018-08-23 11:39:13 | 7 Cheap Biotech Stocks to Buy Now

2018-08-20 08:20:00 | Recent Analysis Shows Ferroglobe, AXT, ChemoCentryx, RedHill Biopharma, GTx, and Achillion Pharmaceuticals Market Influences — Renewed Outlook, Key Drivers of Growth

2018-08-15 16:05:00 | Achillion Expands Management Team With Appointment of Anthony S. Gibney as Chief Business Officer

2018-08-08 19:30:43 | Achillion: 2Q Earnings Snapshot

2018-08-08 16:05:00 | Achillion Reports Second Quarter 2018 Financial Results

2018-07-17 08:14:27 | Achillion Pharmaceuticals: Analysts Are Mostly Positive in July

2018-07-11 11:05:03 | Achillion's 3rd Factor D Inhibitor Enters Clinical Studies

2018-07-10 06:05:00 | Achillion Initiates Phase I First-in-Human Study of ACH-5548, a Third Oral Small Molecule Inhibitor of Complement Factor D